Medisyn agrees natural compound collaboration
that aims to drive the discovery of natural compounds that can
offer safe, natural therapeutic options in the areas of obesity,
immune system and cognitive function.
The alliance opens a new market niche for Medisyn that offers the advantage of a faster time-to-market than traditional new drug development. Terms of the agreement were not disclosed.
Under the terms of the agreement, Humanetics gains access to Medisyn's Fast Forward Engineering platform. Based on molecular topology, the technology enables the discovery and design of novel, compounds for therapeutic use.
The multi-year strategic alliance also aims to exploit Humanetics' ability to deliver non-prescription oral agents, requiring the biotechnology company to invest in the requisite clinical development program to gain eventual FDA approval.
"For Medisyn, this alliance is all about applying our Fast Forward Engineering technology in a new market niche that offers a vastly compressed timeframe for bringing qualified products to market," said David Land, Medisyn's president,
"Medisyn's entry into natural, non-prescription therapeutics is being launched in parallel with the company's existing development work for traditional pharmaceutical customers."
